期刊文献+

乳腺癌细胞免疫逃逸能力的研究 被引量:3

The research of the differences of invasiveness and immune evasion between breast cancer cell lines
原文传递
导出
摘要 目的观察乳腺癌细胞株MCF-7和MDA-MB-231侵袭能力和免疫逃逸能力的差异。方法以Transwell小室进行人工基底膜侵袭实验检测1. 0 × 105个/孔MCF-7细胞和MDA-MB-231细胞侵袭能力的差异;不同浓度混合淋巴细胞与5.0 × 103个/孔乳腺癌细胞株共培养检测MCF-7细胞和MDA-MB-231细胞免疫逃逸能力的差异。结果MDA-MB-231细胞侵袭细胞数量高于MCF-7细胞侵袭细胞数量(86.64 ±7.13比12.27 ±2.53),差异有统计学意义(P〈0.05);与2.5 × 104个/孔、5.O× 104个/孔、1. 0 × 105个/孔、2. 0 × 105个/孔混合淋巴细胞共垮养后,MDA-MB-231细胞存活率髙于 MCF-7 细胞存活率[(1.31 ±0.04)% 比(0. 97 ±0. 01)% ;(1.31 ±0.03)% 比(0.80 ±0.01)% ;(1.43 ±0. 00)% 比(0.60 ±0. 01)% ;(1.57 ±0.09)% 比(0. 59 ±0. 01)% ],差异有统计学意义(P 〈0. 05)。结论MDA-MB-231细胞株较MCF-7细胞株有更强的侵袭能力和免疫逃逸能力。 Objective To study the differences of invasiveness and immune evasion between MCF-7and MDA-MB-231 in vitro. Methods Transwell was used to analyze the difference of invasiveness be-tween 100 thousands per hole MDA-MB-231 and MCF-7 ; Co-culturing with 5 thousands per hole breastcells mixed by various concentrations of lymphocytes was used to observe the difference of immune evasionbetween MDA-MB-231 and MCF-7. Results MDA-MB-231 invaded more cells than MCF-7 (86.64 ±7. 13 vs 12. 27 ±2. 53, P 〈 0. 05) ; The survival rate of MDA-MB-231 was higher than that of MCF-7 co-culturing with 25 thousands per hole, 50 thousands per hole, 100 thousands per hole, 200 thousands perhole lymphocytes [(1.31 ±0.04)% vs (0.97 ± 0. 01 ) % , P 〈 0. 05; (1.31 ±0,03)% vs (0.80 ±0.01)%,P〈0. 05; (1.43 ± 0.00)% vs (0.60 ±0.01)%,p 〈0.05; (1.57 ±0,09)% vs (0. 59 ±0. 01 )% , P 〈0. 05] . Conclusion Our results suggest that MDA-MB-231 cells display stronger invasive-ness and immune evasion.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2013年第4期661-663,共3页 Chinese Journal of Experimental Surgery
基金 国家自然科学基金资助项目(30972935)
关键词 乳腺癌 侵袭 转移 免疫 Breast carcinoma Invasiveness Metastasis Immune
  • 相关文献

参考文献8

二级参考文献44

  • 1Kloos DU,Choi C,Wingender E.The TGF-beta-Smad network:introducing bioinformatic tools.Trends Genet,2002,18:96-103.
  • 2Chorna I,Bilyy R,Datsyuk L,et al.Comparative study of human breast carcinoma MCF-7 cells differing in their resistance to doxorubicin:effect of ionizing radiation on apoptosis and TGF-beta production.Eksp Onkol,2004,26:111-117.
  • 3Tang B,Vu M,Booker T,et al.TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression.J Clin Invest,2003,112:1116-1124.
  • 4Wakefield LM,Roberts AB.TGF-beta signaling:positive and negative effects on tumorigenesis.Curr Opin Genet Dev,2002,12:22-29.
  • 5Deguchi R,Takagi A,Kawata H,et al.Association between CagA+ Helicobacter pylori infection and p53,bax and transforming growth factor-beta-RⅡ gene mutations in gastric cancer patients.Int J Cancer,2001,91:481-485.
  • 6Calin GA,Gafa R,Tibiletti MG,et al.Genetic progression in microsatellite instability high colon cancers correlated wit clinico-pathological parameters:A study of the TGF-βRⅢ,BAX,HMSH3,HMSH6,IGFⅡR,and BLM gene.Int -235.J Cancer,2000,89:230.
  • 7Hazelbag S,Gorter A,Kenter GG,et al.Transforming growth factor-beta1 induces tumor stroma and reduces tumor infiltrate in cervical cancer.Hum Pathol,2002,33:1193-1199.
  • 8Yamada SD,Baldwin RL,Karlan BY.Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors.Gynecol Oncol,1999,75:72-77.
  • 9Ten Dijke P,Goumans MJ,Itoh F,et al.Regulation of cell proliferation by Smad proteins.J Cell Physiol,2002,191:1-16.
  • 10Siegel R, Naishadham D ,Jemal A. Cancer statistics ,2012. CA Cancer J Clin ,2012,62 : 10-29.

共引文献28

同被引文献27

  • 1高德宗,孙靖中,余之刚,唐鲁兵,王成刚,江立玉.γ-干扰素增强他莫昔芬抗ER阴性乳腺癌细胞作用的实验研究[J].中国肿瘤生物治疗杂志,2005,12(3):215-217. 被引量:3
  • 2Coster S, Fallowfield LJ. The impact of endocrine therapy on patients with breast cancer: a review of the literature [ J ]. Breast, 2002, 11 (1) :1-12.
  • 3Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for preven- tion of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study[ J]. J Natl Cancer Inst,2005,97 (22) : 1652-1662.
  • 4Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer preven- tion trial[ J]. J Natl Cancer Inst,2007,99 (4) :283-290.
  • 5Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the pre- vention of breast cancer :late results of the Italian Randomized Tamox- ifen Prevention Trial among women with hysterectomy [ J ]. J Natl Cancer Inst,2007,99 (9) :727-737.
  • 6Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized I- BIS-I trial[ J ]. J Natl Cancer Inst,2007,99 (4) :272-282.
  • 7Reimers L, Crew KD. Tamoxifen vs raloxifene vs exemestane for che- moprevention[ J]. Curt Breast Cancer Rep ,2012,4(3 ) :207-215.
  • 8Wang KL, Hsia SM, Yeh JY, et al. Anti-proliferative effects of evodia- mine on human breast cancer cells [ J ]. PLoS One, 2013,8 ( 6 ) : e67297.
  • 9Medrek C,Pontén F,Jirstrom K,et al.The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients[J].BMC cancer,2012,12:306.
  • 10Salameh TS,Le TT,Nichols MB,et al.An ex vivo co-culture model system to evaluate stromal-epithelial interactions in breast cancer[J].Int J Cancer,2013,132:288-296.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部